Study identifies cellular tipping point in Alzheimer’s progression

Researchers Identify Biological Tipping Point in Alzheimer’s Progression

A sweeping new study has uncovered what researchers describe as a critical cellular transition that may determine whether Alzheimer’s disease leads to dementia — offering fresh clues about why some people remain cognitively sharp despite carrying the disease’s hallmark brain pathology.

The research, published June 4 in Nature Medicine by scientists from VIB, KU Leuven, the UK Dementia Research Institute, and Muna Therapeutics, maps six distinct tissue domains representing a spatial continuum of Alzheimer’s progression. At the center of the findings is a shift in microglia — the brain’s resident immune cells — from an inflammatory state associated with amyloid-beta plaques to an antigen-presenting state that emerges alongside tau pathology and neurodegeneration.nature

A Cellular Switch Toward Dementia

Using spatial transcriptomics and single-cell sequencing on human donor brain tissue, the team identified a key inflection point between early disease stages dominated by amyloid plaques and later stages marked by tau tangles and neuronal loss. Before that transition, microglia mount an inflammatory response to plaques. After it, they adopt an antigen-presenting phenotype that appears to coincide with the onset of cognitive decline.news-medical

“This has been an exciting journey with many partners. The study, entirely based on human donor material, provides insight into one type of resilience mechanism in the progression of AD to dementia,” said Bart De Strooper, professor at KU Leuven and VIB group leader, and a co-senior author of the study.news-medical

Two Distinct Paths to Resilience

Perhaps the most striking finding involves how certain individuals resist dementia despite carrying Alzheimer’s pathology. Octogenarians who accumulated amyloid plaques but remained cognitively healthy showed an early microglial response that never transitioned into the later, disease-associated immune state. Centenarians exhibited a different mechanism: they activated the later microglial program, but it was decoupled from tau accumulation and its damaging effects.news-medical

“Understanding better how the brain resists the disease will provide new avenues towards therapies to prevent neurodegeneration and dementia,” said Mark Fiers of VIB-KU Leuven, a co-senior author.news-medical

Therapeutic Implications

The findings point toward microglial state transitions — and pathways such as TREM2 — as potential therapeutic targets. Interventions that preserve beneficial early microglial responses or prevent the shift to the antigen-presenting state could be most effective if applied before the brain reaches the tipping point, according to the researchers.news-medical

“These findings open new opportunities to target microglial states and extend resilience rather than simply focusing on plaque removal,” said Niels Plath, chief scientific officer of Muna Therapeutics. Muna is currently running a Phase 1 trial of its oral TREM2 agonist, MNA-001, which aims to boost protective microglial function in early Alzheimer’s disease.munatherapeutics